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Background: We recently reported that epithelial–mesenchymal transition (EMT) is active 
in the airways in chronic obstructive pulmonary disease (COPD), suggesting presence of 
an active profibrotic and promalignant stroma. With no data available on potential treatment 
effects, we undertook a blinded analysis of inhaled corticosteroids (ICS) effects versus placebo 
on EMT markers in previously obtained endobronchial biopsies in COPD patients, as a “proof 
of concept” study.
Methods: Assessment of the effects of inhaled fluticasone propionate (FP; 500 µg twice daily 
for 6 months) versus placebo in 34 COPD patients (23 on fluticasone propionate and eleven on 
placebo). The end points were epidermal growth factor receptor (EGFR; marker of epithelial 
activation) and the biomarkers of EMT: reticular basement membrane (Rbm) fragmentation 
(“hallmark” structural marker), matrix metalloproteinase-9 (MMP-9) cell expression, and 
S100A4 expression in basal epithelial and Rbm cells (mesenchymal transition markers).
Results: Epithelial activation, “clefts/fragmentation” in the Rbm, and changes in the other 
biomarkers all regressed on ICS, at or close to conventional levels of statistical significance. 
From these data, we have been able to nominate primary and secondary end points and develop 
power calculations that would be applicable to a definitive prospective study.
Conclusion: Although only a pilot “proof of concept” study, this trial provided strong sug-
gestive support for an anti-EMT effect of ICS in COPD airways. A larger and fully powered 
prospective study is now indicated as this issue is likely to be extremely important. Such stud-
ies may clarify the links between ICS use and better clinical outcomes and protection against 
lung cancer in COPD.
Keywords: pilot trial, reticular basement membrane, S100A4, EGFR, MMP-9, lung cancer
Background
Smoking-related chronic obstructive pulmonary disease (COPD) is the fourth most 
common cause of chronic disability and death in developed countries.1 Our limited 
insights into the details of airway remodeling in the airway wall in COPD mainly date 
from the 1960s, and our knowledge about the effects of inhaled corticosteroids (ICS) 
on such airway remodeling is scanty. This is especially true of data from endobron-
chial biopsies done in nonoperative volunteer patients, which contrasts with copious 
such studies on asthma.2
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We have recently reported novel characteristics of airway 
remodeling in active smokers. These changes are especially 
marked in those with established COPD. The subepithelial 
reticular basement membrane (Rbm) was variably thickened 
but also markedly fragmented with clefts or elongated spaces 
within it,3–8 which is quite different from that in asthma 
(Figure 1), where the Rbm is homogeneously thickened and 
hyaline in appearance.9 These elongated clefts in the Rbm in 
COPD are usually not empty, but frequently contain cells.3 
These cells positively express the mesenchymal markers 
S100A4 and vimentin, as well as matrix metalloproteinase-9 
(MMP-9),3 and do not penetrate inflammatory or other 
immune cells.4 These changes are “classic” hallmarks of the 
process termed epithelial–mesenchymal transition (EMT),10,11 
defined as the transition of epithelial cells to a mesenchymal 
phenotype with the potential to digest and migrate through 
the Rbm to the subepithelial lamina propria.10,11 The epithe-
lium in COPD is also highly activated, with upregulation of 
epidermal growth factor receptor (EGFR).3 In general, these 
changes were most marked in currently smoking COPD sub-
jects compared with ex-smoking COPD and physiologically 
normal smokers. We have also demonstrated hypervascularity 
in and around the Rbm,9,12 which would characterize the EMT 
in COPD as being Type III.5–8,11,13
Vessel changes seemed much the same in both smoker 
groups (with COPD or not), and much less marked in 
ex-smoker COPD subjects, which suggests that vessel 
changes were mainly effects of smoking. Type III EMT is 
recognized as producing a highly dangerous pro-cancerous 
stroma immediately under the epithelium. Of course, we 
recognize that smoking, and especially COPD is closely 
related to lung cancer development,14 and such promalignant 
stroma has been described as being important in the develop-
ment of other common epithelial malignancies.15 ICS have 
become standard treatment in severe COPD, on the basis of 
positive empirical results from large studies, demonstrat-
ing short-term improvement in lung function and longer 
term benefits in terms of quality of life, exacerbation rates, 
long-term physiological decline, and possibly mortality.16 
Importantly, there are also reports about the effects of ICS 
on inflammatory stromal airway changes in COPD;17 there 
is also epidemiological and circumstantial evidence of a 
protective effect of ICS use against lung cancer development 
in the highly vulnerable COPD population.18,19
To our knowledge, there have been no longitudinal 
trials published about the effects of ICS on EMT or other 
airway structural changes in COPD. In such a situation, the 
performance of a pilot trial has been advocated.20,21 Given 
published evidence linking EMT and epithelial cancers in 
general, and the potential effects of ICS on lung cancer risk, 
we believed that a pilot randomized trial evaluating the 
effects of ICS on EMT markers in COPD was warranted 
and so this “proof of concept” study was undertaken. This 
was a prospective analysis under blinded conditions that uti-
lized tissue available from a previous study mainly directed 
at documenting changes in airway inflammatory cells,17 
although it was always a stated intention to address airway 
remodeling at an appropriate time.
Methods
Using retrospectively obtained tissue, this study still con-
stituted a prospective, double-blinded, randomized, and 
placebo-controlled study (Figure 2), but was intended as 
a pilot investigation given the paucity of data on the likely 
effects of ICS on the parameters of interest. A pilot study does 
not require a formal sample size calculation but is a precursor 
exercise to test whether the components of subsequent larger 
studies can work well together. Pilot studies provide valuable 
information such as that on patient recruitment and retention, 
the practicability of performing investigations, and an esti-
mate of effect sizes, where no other information exists. The 
pilot study data may be analyzed as an “external pilot”, and 
it is understood that results from hypothesis testing should be 
treated as preliminary, with robust but pragmatic statistical 
management, and therefore, cautious interpretation.21 The 
details of the study design (full protocol available from the 
Figure 1 rbm fragmentation in COPD.
Notes: Bronchial biopsy specimen from a COPD current smoker, black arrows 
showing rbm fragmentation with many “clefts” containing cells. stain: h&e.
Abbreviations: COPD, chronic obstructive pulmonary disease; h&e, hematoxylin 
and eosin; rbm, reticular basement membrane.
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authors) and data on inflammatory cell profiles have been 
published previously.17
subjects
The demographics of the study groups are presented in 
Table 1. The study was approved by “The Human Research 
Ethics Committee (Tasmania) Network” and “The Alfred 
Health Human Ethics Committee” Melbourne (The Alfred 
Hospital), and is registered with the national trials registry 
(ANZCTR, Trial ID: ACTRN12612001111864). All subjects 
gave written, informed consent prior to participation. Details 
of subjects were published previously.17,22 The clinical study 
was performed over 2000–2002, with an initial analysis 
of inflammatory cells,17 although it was always intended 
to analyze “remodeling” changes. Time has been taken up 
as we cross-sectionally analyzed the details and relevance 
of the structural changes we subsequently observed,3,4 and 
with the previous use of tissue, it meant that more limited 
matched pairs of biopsy sections were available for this set 
of analyses. Further, randomization was originally done on a 
2:1 basis of active to placebo treatment because at the time it 
was considered that the most useful data would be obtained 
in the active (ICS) limb, and this too limited our statistical 
power in the between-group comparisons. The control tissue 
was available from clinically and physiologically normal, 
age-matched non-smoker individuals who had volunteered 
Assessed for eligibility (n=36)Enrollment =36
Allocation
Follow-Up
Analysis
Randomized (n=34)
Excluded (n=2)
♦ Not meeting inclusion criteria (n=0)
♦ Declined to participate (n=2)
♦ Other reasons (n=0)
Allocated to intervention (n=23)
♦ Received allocated intervention (n=23)
♦ Did not receive allocated intervention (give
    reasons) (n=0)
Allocated to intervention (n=11)
♦ Received allocated intervention (n=11)
♦ Did not receive allocated intervention (give
    reasons) (n=0)
Analyzed (n=5)
♦ Excluded from analysis (give reasons) (n=0)
Analyzed (n=13)
♦ Excluded from analysis (give reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=5)
Had side effects (n=3)
Severe exacerbation (n=1)
Lack of adherence (n=1)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=3)
Refused for 2nd biopsy (n=1)
Did not have enough paired tissue (n=2)
Figure 2 study design.
Notes: Thirty-four COPD patients; 2-week run-in period; then bronchoscopy and airway biopsy; then patients randomized 2:1 by research nurses into receiving fluticasone 
propionate or placebo for 6 months by using a computer-generated random-numbers table; bronchoscopy and airway biopsy then repeated.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 1 Demographics
Groups (numbers) FP  
(n=23)
Placebo  
(n=11)
Normal 
controls
age (years) 61 (46–69) 61 (52–69) 44 (20–68)
Female/male 9/14 4/7 7/8
Current smoker/ex-smoker 13/10 4/7 n/a
Pack-year smoking history 44 (18–150) 51 (22–148) n/a
gOlD stage I/II† 12/11 5/6 n/a
FeV1/FVC ratio 
(post-BD)*
59 (41–68) 57 (38–68) 82 (71–88)
Notes: †Diagnosis of mild-to-moderate COPD was made according to gOlD 
guidelines; *post-BD values after 400 µg of albuterol. There was no statistically significant 
difference between the groups at baseline. Data are expressed as medians and ranges.
Abbreviations: BD, bronchodilator; COPD, chronic obstructive pulmonary disease; 
FeV1, forced expiratory volume in 1 second; FP, fluticasone propionate; FVC, forced 
vital capacity; gOlD, global Initiative for Chronic Obstructive lung Disease; n/a, 
not available
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for research bronchoscopy over a number of years, and their 
endobronchial biopsies had been stored and then processed 
in the same way as for the longitudinal intervention subjects.3 
Exclusion criteria include: 1) subjects with a history sug-
gestive of asthma, which includes symptoms in childhood, 
related atopic disorders, eczema or hay fever, substantial 
day-to-day variability or prominent nocturnal symptoms, or 
a history of wheeze rather than progressive breathlessness, 
and any who had previously used ICS (oral or inhaled); 2) no 
major comorbidities such as uncontrolled diabetes, angina, 
or cardiac failure, nor other coexisting respiratory disorders 
including pulmonary fibrosis, lung cancer, or bronchiectasis, 
and subjects were not on medication; and 3) subjects who 
were unable to give written informed consent. Inclusion 
criteria include: 1) current-smokers with COPD aged 40–70 
years with a smoking history equal to or more than 15 pack-
years; subsequently obtained bronchoalveolar lavage (BAL) 
fluid had to be free of culturable bacteria; forced expiratory 
volume in 1 second (FEV1) 40%–80% predicted, with forced 
expiratory ratio (FER; ratio of FEV1 to forced vital capacity 
[FVC]) #70% post-bronchodilator with definite scalloping 
out of the descending limb of the flow–volume loop on 
spirometry. COPD in ex-smokers with 6 months of smoking 
cessation were included; and 2) normal healthy never smok-
ing controls also underwent bronchoscopic examination and 
physiological evaluation. They were at least 18 years old with 
a FEV1/FVC ratio of 70% or higher and FEV1% predicted of 
80% or higher; they had no history of respiratory illness.
Bronchoscopy
Bronchoscopy and endobronchial biopsies were performed 
in the standard way, as previously described.2
Immunostaining
Tissue was processed as previously described.3,4 Following 
removal of paraffin, followed by hydration, sections were 
stained with these antibodies: monoclonal-anti-MMP-9 
(R&D Systems, Inc., Minneapolis, MN, USA; MAB911; 
1:50 for 2 hours), monoclonal-anti-EGFR (Chemicon S/A, 
São Paulo, Brazil; CBL417; 1:40 for 60 minutes), and anti-
S100A4 polyclonal antibody (Dako, Glostrup, Denmark; 
A5114; 1:2,500 for 90 minutes). In each case, a non-immune 
immunoglobulin (Ig)G1 negative control (Dako; X0931 
clone DAK-GO1) was performed to eliminate false positive 
staining and a positive tissue control (surgically resected lung 
tissue) was also used. Bound antibodies were elaborated using 
peroxidase-labeled EnVision™ + (Dako; K4001) and liquid 
diaminobenzidine (DAB) + (Dako; K3468).
Biopsy analysis
Computer-assisted image analysis was performed with a 
Leica DM 2500 microscope (Leica Microsystems,  Wetzlar, 
Germany), Spot insight 12 digital camera (Diagnostic 
Instruments, Inc., Sterling Heights, MI, USA), and Image 
Pro (v5.1; Media Cybernetics, Inc., Rockville, MD, USA) 
software. All slides were coded and randomized by an inde-
pendent person and then counted by a single experienced 
observer (SSS) blinded to the subject and diagnosis, with 
quality assurance on randomly selected slides provided by a 
clinical and academic pathologist (Professor Hans Konrad 
Muller; International Academy of Pathology and Royal Col-
lege of Pathologists of Australasia, Sydney, Australia).3,4
Quantification of indices was performed before and after 
treatments to compare the effects of interventions. Cellular 
staining changes in the basal epithelium and Rbm were 
documented. Cell numbers positive for S100A4 and MMP-9 
and the number of vessels within the Rbm were normalized 
for purposes of comparisons relative to the total length of 
basement membrane assessed. EGFR was measured as a 
percentage of epithelium stained for EGFR over the total 
basement membrane length. Although the full picture of frag-
mentation of the Rbm includes linear “clefts” or elongated 
spaces/cracks in the Rbm, as fragments of Rbm commonly 
“hang off ” and with similar pieces completely separated 
from the remainder (Figure 1), we have used Rbm linear 
splitting (ie, cleft formation) as a quantitative measure for 
the observation. Thus, the total length of splits was summed 
and normalized as a percentage of the length of Rbm. Normal 
control data were provided from physiologically normal, 
non-smoking, age-matched individuals, obtained previously 
in a published cross-sectional study.3
statistical analyses
At the time of developing this pilot investigation, there were 
no data on which to base power calculations. In keeping with 
the principles of such a pilot study, our analyses were pre-
dominantly exploratory by definition, with no formal sample 
size calculable. Recommendations for good practice are that 
where possible, approximately 20–30 patients at baseline 
should be evaluated, as in the present study, to investigate 
the distribution of outcomes of key study parameters.21,23 
A limited set of hypotheses were tested, complementing 
descriptive data. We had one end point on epithelial activa-
tion, one on a structural change classically associated with 
EMT, and two putative mesenchymal biomarkers of EMT 
(S100A4 and MMP-9 expression, with the former analyzed 
separately in basal epithelium and Rbm cells).
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The data subsequently reported were generally skewed, 
so results are presented as medians and ranges and non-
parametric analyses of variance were performed. The effects 
of the interventions were assessed using Wilcoxon related-
samples tests to compare the indices for each of the biomark-
ers before and after treatment within treatment groups and 
also as changes within the groups (active versus [vs] placebo). 
The differences between the indices for the placebo and ICS 
treatment groups after intervention and differences from 
normal controls were compared using the Mann–Whitney 
test. These statistical analyses were performed using SPSS 
(v15.0 for Windows; IBM Corporation, Armonk, NY, USA) 
with a two-tailed P#0.05 considered statistically significant. 
In this exploratory analysis, no primary or secondary end 
points have been discriminated, and as regarded reasonable 
under the conditions of a pilot study,20,21 no statistical allow-
ance was made for the potential problem of multiple and 
collinear comparisons.
sample size and power calculations,  
with putative primary and secondary outcomes
From the data obtained, we estimated the sample size required 
for a definitive study that would include “full” statistical 
analysis of drug affect, including allowance for multiple 
comparisons. We prospectively specified a three-stage, fixed-
sequence statistical testing procedure and adjusted “alpha” 
(power) for multiplicity accordingly.24 Firstly, we would 
specify EGFR expression in the epithelium as the primary 
“driving” outcome measure and test the null hypothesis of 
no difference using alpha =0.05. If the null hypothesis cannot 
be rejected there would be a rationale for no further testing. 
However, given the mechanistic uncertainty between EGFR 
upregulation and EMT, we have nominated a coprimary 
hypothesis related to the main descriptive structural hallmark 
of EMT, namely the aggregate lengths of splitting in the 
Rbm that could therefore also be tested using alpha =0.05. 
If appropriate, ie, if the null hypothesis is rejected, in the 
third stage of testing we would treat the remaining outcomes, 
(basal cell S100A4, Rbm cell S100A4, and MMP-9 expres-
sion) as a cluster of related end points with an overall and 
shared alpha, so that individual hypotheses would be tested 
using an alpha of 0.0167; subsequently, larger and/or more 
consistent changes would be required.
Results
Studying markers of EMT in airway biopsies proved prac-
ticable in a randomized trial setting. Recruitment, random-
ization and allocation concealment, 6 months of treatment, 
and assessments including two bronchoscopies, were all 
practicable and acceptable to patients.22 The groups were 
reasonably well-matched for demographics and lung function 
(Table 1). All five pathological features of interest at baseline 
were significantly abnormal in COPD patients compared to 
normal controls.3
egFr expression (as marker of 
activation) in the airway epithelium
The percentage area of EGFR staining in the epithelium 
was statistically significantly lower after treatment for the 
ICS group (median [range]: 34% [14.6–59.5] before vs 
5.8% [2.6–43.8] after; P,0.03) but not for the placebo 
group (14.4% [3.6–38.2] before vs 10.3% [1.3–39.1] after 
treatment; P=0.3; Figure 3). The active arm was essen-
tially normalized after the ICS treatment (P=0.9 vs normal 
controls). There was modest evidence for aggregate change 
over time on ICS for EGFR relative to changes on placebo 
(P=0.06), but with the removal of a single extreme outlier, 
this was statistically significant (P,0.03).
Fragmentation within the rbm
The lengths of splitting of the Rbm (length of splitting/
total Rbm length ×100) was statistically significantly lower 
P<0.03
P=0.3
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Figure 3 egFr expression.
Notes: egFr expression as a percentage of the total epithelial area before and after 
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treatment, the active group was not statistically significantly different to normal 
controls (P=0.9). Data are represented as medians and ranges.
Abbreviations: egFr, epidermal growth factor receptor; ICs, inhaled corti costeroids.
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after treatment for the ICS group (median [range]: 19.2% 
[0.2–42.8] before vs 1.9% [0–29.2] after treatment; P,0.03) 
but not for the placebo group (24.0% [6.6–100] before 
vs 26.9% [2.5–48.5] after treatment; P=0.4; Figure 4). 
Posttreatment, the active treatment arm had statistically 
significantly less splitting than the placebo group (P,0.02; 
Figure 4), and Rbm splitting for the ICS group was not sta-
tistically significantly different from normal controls (P=0.4). 
There was modest evidence for an effect of ICS on aggregate 
change in fragmentation relative to placebo (P=0.06), but 
again, after the removal of a single outlier, this was again 
statistically significant (P,0.03).
s100a4 positive cells  
in the basal epithelium
Cell staining (Figure 5) for S100A4 within the basal lay-
ers of the airway epithelium was statistically significantly 
lower after treatment for the ICS group (median [range]: 
25.8 per mm [2.4–55.3] before vs 12.3 per mm [0.6–24.9] 
after; P,0.004) but not for the placebo group (19.8 per mm 
[2.9–31.6] before vs 17.4 per mm [10.3–35.5] after treat-
ment; P=0.4). However, at the end of the treatment phase, the 
active arm was still showing statistically significantly higher 
numbers for S100A4 than for normal controls (P,0.03), 
ie, they were not fully normalized. Changes over time on 
ICS were also statistically significant compared to those on 
placebo (P,0.009; Figure 5).
s100a4 positive cells in the rbm
Cell numbers in the Rbm positive for S100A4 were 
statistically significantly fewer after treatment for the ICS 
group (median [range]: 44.4 per mm [15.3–92.6] before vs 
20.8 per mm [2.6–60.7] after; P,0.02) but not on placebo 
(23.1 per mm [14–82.9] before vs 29.3 per mm [3.6–48.1] 
after treatment; P=0.6; Figure 6). However, even after ICS, 
the cell numbers were still statistically significantly higher 
compared to normal controls (P,0.004), ie, they were not 
fully normalized. Aggregate individual changes on ICS 
were also statistically significantly greater than on placebo 
(P,0.002; Figure 6).
MMP-9 positive cells in the rbm
MMP-9 positive cells decreased statistically significantly in 
the Rbm in the treatment arm (median [range]: 0.5 per mm 
[0–4.3] before vs 0 per mm [0–0.6] after treatment; P,0.02) 
but did not change within the placebo group (1.1 per mm 
[0–4.1] before vs 1.3 per mm [0–2.7] after treatment; P=0.8; 
Figure 7). After treatment, the active ICS treatment arm had 
statistically significantly fewer cells positive for MMP-9 in 
Rbm than did the placebo group (P,0.05; Figure 7). Further, 
MMP-9 positive cell numbers in the active arm became quite 
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placebo group (P,0.02). after treatment, fragmentation was normalized compared 
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similar to normal control values after treatment (P=0.3). 
However, individual changes in MMP-9 expression over 
6 months on ICS were not statistically significantly different 
to changes on placebo (P=0.3).
Post hoc power calculations
Based on our pilot data for 22 individuals, for the nominated 
primary outcome of change in EGFR, a total sample size of 
36 (18 per balanced treatment group) would provide 80% 
power to detect the observed difference in mean change. 
This sample size would provide 65% power (α=0.05) to 
detect the observed difference in Rbm splitting (for 80% 
power, 52 would be required), 97% power (α=0.0167) for 
basal S100A4 (for 80% power, only 26 would be required), 
48% power for Rbm S100A4, and 31% power for MMP-9. 
The sample sizes required to achieve 80% power for each of 
these secondary outcomes individually would be 26, 70, and 
104 respectively, given the stringent conditions imposed by 
allowing for multiple comparisons (Table 2).
Discussion
We have previously shown that EMT is likely to be an active 
process in smokers’ airways, but is especially marked in cur-
rent smokers with COPD.3,4 These findings were based on 
immunostaining for acknowledged “classic” empiric EMT 
markers10,11,25,26 and based especially on criteria for in vivo 
research on EMT as suggested by Zeisberg and Neilson.10 
Recent papers by Milara et al27 and Wang et al28 have con-
firmed the potential for EMT as a major mechanism for small 
airway fibrosis (EMT Type II) in COPD. We have hypoth-
esized that large airway EMT, which we have found is also 
associated with Rbm hypervascularity, may be important in 
both fibrosis and cancer pathogenesis and progression, as 
this is typical of what has been described as procancerous 
for epithelial tumors elsewhere.5–8,15 In this pilot random-
ized controlled trial, we have provided consistent but still 
provisional evidence that ICS over 6 months suppresses such 
EMT-related changes. We feel that the study was successful, 
at the very least, as a “proof of concept” study.
Our pilot trial indicated that intervention studies using 
bronchoscopic airway material for studying EMT in COPD 
are practicable, and we were able to provide reliable data 
regarding baseline levels and reproducibility of markers 
of EMT, as well as changes associated with ICS treatment, 
albeit in a pilot setting. For developing power calculations and 
sample size, we have now defined our primary end points as 
Rbm fragmentation (a classic structural hallmark of EMT) 
and epithelial activation, and the other downstream EMT 
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Figure 7 MMP-9 expression in rbm.
Notes: The number of MMP-9 positive cells in rbm clefts per mm of rbm before 
and after ICs versus before and after placebo, with normal control data for 
comparison. Posttreatment, the active treatment arm had statistically significantly 
fewer MMP-9 positive cells than the placebo group (P,0.05). after treatment, the 
active group was not statistically significantly different to normal controls (P=0.3). 
Data are represented as medians and ranges.
Abbreviations: rbm, reticular basement membrane; ICs, inhaled corticosteroids; 
MMP-9, matrix metalloproteinase-9.
P<0.002
P<0.02
P=0.6
Be
for
e I
CS
Aft
er 
ICS
Be
for
e p
lac
eb
o
Aft
er 
pla
ce
bo
No
rm
al 
co
ntr
ols
N
u
m
b
er
 o
f 
S
10
0A
4 
+v
e 
ce
lls
 in
R
b
m
 p
er
 m
m
 o
f 
R
b
m
0
20
40
60
80
100
Figure 6 s100a4 expression in rbm.
Notes: number of s100a4 positive cells in the rbm before and after ICs versus 
before and after placebo, with normal control data for comparison. Changes over 
time with ICS were also statistically significant compared to those on placebo 
(P,0.002). After treatment, the active group was statistically significantly different 
to normal controls (P,0.004). Data are represented as medians and ranges.
Abbreviations: rbm, reticular basement membrane; ICs, inhaled corticosteroids.
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biomarkers of MMP-9 cell expression, in addition to S100A4 
cell expression in the basal epithelium and Rbm, as secondary 
end points. The results of this analysis would suggest that if 
powering a study for these primary end points, then rather 
modest numbers are required. If S100A4 expression in the 
basal epithelium was treated as an independent variable, it 
would provide the most sensitive outcome, and perhaps a pri-
mary end point of combining S100A4 staining in both basal 
epithelial cells and Rbm together would be worth considering 
in numerically limited intervention studies.
The present study supports the concept that the epithelium 
in smokers/COPD is activated with high levels of EGFR 
expression. We nominated this as a primary outcome in the 
power calculations because it may well be that activation of 
the epithelium is a primary mechanistic event in inducing 
EMT and could also be important in cancer induction.29 
This pilot trial showed a reduction in EGFR expression in 
the airway epithelium in the active ICS arm compared to 
placebo, and again, it was essentially normalized. EGFR 
is overexpressed in many types of cancers, including non-
small-cell lung cancer,29 and we have shown that this is highly 
expressed in the epithelium as part of the “COPD–EMT 
phenotype signal”.3 This is the first report of the effects of 
ICS on epithelial activation in COPD.
Taken together, these data provide strong suggestive 
evidence that fluticasone propionate could have significant 
anti-epithelial activation and anti-EMT effects in COPD, but 
is seemingly not able to completely eliminate all manifesta-
tions of EMT activity in COPD airways in all subjects over 
this 6-month timescale. We did not have sufficient numbers of 
samples to adequately address the question of whether current 
smoking status influences the effects of ICS on EMT markers; 
however, there was no obvious difference between these two 
groups in any of the biomarker changes on active treatment.
Given that this study was treated as a pilot for “proof of 
concept” and investigative power-determination purposes, 
with assumed insufficient numbers of participants to be a 
definitive study, we have avoided some statistical finesse, such 
as allowing for multiple comparisons, or treating primary 
versus secondary end points differently. Under such pilot 
circumstances, this is regarded as quite acceptable,20,21 but 
we have now provided evidence for how a larger definitive 
study could be designed.
The presence of COPD per se increases the risk of devel-
oping lung cancer by four- to fivefold when the smoking 
history is controlled for.18 Furthermore, up to 70% of lung 
cancer occurs in the context of mild-to-moderate COPD 
rather than end-stage.30 This implies that mechanisms specific 
to the relatively early pathogenesis of COPD may be involved 
in the development of lung cancer. Potential shared biologi-
cal mechanisms in COPD and lung cancer include: chronic 
inflammation, matrix degradation, cell proliferation and anti-
apoptosis, abnormal wound repair, and angiogenesis.31 All 
of these are associated with EMT, especially EMT Type III, 
which is recognized as a promalignant condition in other 
situations of potential epithelial malignancy.11 Indeed, the 
relationship between COPD pathology and carcinogenesis 
may reflect a more general paradigm of epithelial instability 
and cancer etiology, bearing in mind that epithelial cancers 
make up 90% of all malignancies.15
A number of observational studies in the literature have 
demonstrated that ICS reduce local and systemic inflamma-
tion among patients with COPD.17,32 ICS also improves lung 
function and the frequency of exacerbation in long-term 
users.33 Animal models of smoking-induced COPD have 
demonstrated that glucocorticoids strikingly inhibit the devel-
opment of smoking-related lung cancer.34–36 In human epide-
miological research, a US veterans cohort study of 10,474 
patients in primary care clinics found that use of ICS, albeit 
only at high doses (as used in our study), was associated with 
appreciable (50%) decreased risk of lung cancer.18 Similar 
findings were reported in ex-smokers with COPD.19 However, 
Table 2 From the data obtained in the pilot study: observed mean and sD for changes in epithelial activation and eMT biomarkers for 
the placebo and ICs groups over 6 months of intervention and sample sizes required for 80% power for change for each end point in 
future potential studies (the secondary end points stringently share an α of 0.05)
Marker Placebo ICS Difference N for 80% power: 
primary outcome
N for 80% power: joint 
secondary outcomeN Mean SD N Mean SD
egFr* 7 –0.42 0.68 10 –1.32 1.19 –0.90 36
rbm splitting* 7 0.34 0.98 14 –2.19 3.22 1.85 52
Basal s100a4 7 2.65 13.1 14 –14.2 13.1 –16.9 18 26
rbm s100a4 8 –4.93 15.6 11 –20.1 22.7 –15.1 24 70
MMP-9* 8 –0.03 5.44 11 –2.93 3.53 –2.90 34 104
Note: *Calculated on log-transformed data.
Abbreviations: egFr, epidermal growth factor receptor; eMT, epithelial–mesenchymal transition; ICs, inhaled corticosteroids; MMP-9, matrix metalloproteinase-9; rbm, 
reticular basement membrane; sD, standard deviation.
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the Towards a Revolution in COPD Health (TORCH) study37 
of ICS in severe COPD failed to show this effect, but it was 
not powered to pick this up, and was a study on severe rather 
than mild-to-moderate COPD, where lung cancer tends to 
occurs in particular.30 TORCH would have excluded obvi-
ous lung cancer at entry and the study participants could be 
regarded as a survivor population. There is an essential need 
for both in vivo and in vitro human studies to understand the 
mechanistic link between COPD and airway cancer and how 
ICS and other drugs may affect it.38,39
Conclusion
This relatively small pilot study using retrospectively 
obtained tissue has actually provided quite strong suggestive 
evidence for an effect of ICS in downregulating epithelial 
activation and selected EMT biomarkers in COPD airways. 
We hope to have provided a strong stimulus for a larger 
confirmatory study, and have provided estimates of sample 
sizes needed for adequate power for appropriate statistical 
analyses. The numbers of COPD subjects needed to be 
recruited for such a study are quite feasible.
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